Protagonist Therapeutics Inc
PTGX50.690USD
+0.480+0.96%
收盘 07/02, 16:00（美东）报价延迟15分钟
3.14B总市值
10.01市盈率 TTM
关于 Protagonist Therapeutics Inc 公司
Protagonist Therapeutics, Inc. 是一家生物制药公司。该公司使用其肽基化学实体 rusfertide 和 JNJ-2113 进行不同的开发，这些实体均源自其专有的发现技术平台。该公司的临床项目分为两类疾病：血液学和血液疾病以及炎症和免疫调节疾病。其主要临床资产 rusfertide (PTG-300) 是一种可注射的铁调素类似物，正在开发中，用于治疗真性红细胞增多症 (PV) 和其他血液疾病。该公司的白细胞介素-23 受体 (IL-23R) 拮抗剂化合物 JNJ-2113 是一种口服的试验药物，旨在阻断已上市的可注射抗体药物所针对的生物途径。其 PN-943 是一种全资研究的口服肠道限制性 α4β7（α4β7）特异性整合素拮抗剂，用于治疗炎症性肠病（IBD）。
公司简介
公司代码PTGX
公司名称Protagonist Therapeutics Inc
上市日期Aug 11, 2016
成立日期2006
CEODr. Dinesh V. Patel, Ph.D.
员工数量126
证券类型Ordinary Share
年结日Aug 11
公司地址7707 Gateway Blvd Ste 140
城市NEWARK
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编94560-1160
电话15104740170
网址https://www.protagonist-inc.com/
公司代码PTGX
上市日期Aug 11, 2016
成立日期2006
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
357.08K
-0.38%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Ms. Sarah A. O'Dowd
Ms. Sarah A. O'Dowd
Independent Director
Independent Director
--
-100.00%
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Mr. Corey Davis, Ph.D.
Mr. Corey Davis, Ph.D.
IR Contact Officer
IR Contact Officer
--
--
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
--
-100.00%
名称
名称/职务
职务
持股
持股变动
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
357.08K
-0.38%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
13.87%
Farallon Capital Management, L.L.C.
9.85%
RTW Investments L.P.
9.23%
The Vanguard Group, Inc.
6.88%
Deep Track Capital LP
5.24%
Other
54.92%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
13.87%
Farallon Capital Management, L.L.C.
9.85%
RTW Investments L.P.
9.23%
The Vanguard Group, Inc.
6.88%
Deep Track Capital LP
5.24%
Other
54.92%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
33.20%
Investment Advisor
33.04%
Hedge Fund
30.09%
Research Firm
4.41%
Venture Capital
4.17%
Private Equity
1.86%
Individual Investor
1.10%
Pension Fund
1.03%
Bank and Trust
0.35%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
522
67.76M
109.32%
-9.35M
2025Q1
541
67.25M
108.51%
-8.96M
2024Q4
503
65.58M
106.87%
-12.21M
2024Q3
480
64.24M
108.98%
-11.36M
2024Q2
419
61.14M
104.21%
-15.61M
2024Q1
412
61.98M
106.36%
-12.46M
2023Q4
402
59.53M
103.21%
-16.02M
2023Q3
400
59.06M
102.70%
-14.36M
2023Q2
411
59.30M
103.68%
-17.88M
2023Q1
397
55.80M
108.46%
-12.55M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
8.60M
13.87%
-162.95K
-1.86%
Mar 31, 2025
Farallon Capital Management, L.L.C.
6.11M
9.85%
+177.00K
+2.98%
Mar 31, 2025
RTW Investments L.P.
5.72M
9.23%
+220.87K
+4.02%
Mar 31, 2025
The Vanguard Group, Inc.
4.27M
6.88%
+57.18K
+1.36%
Mar 31, 2025
Deep Track Capital LP
3.25M
5.24%
+250.00K
+8.33%
Apr 03, 2025
BVF Partners L.P.
3.21M
5.18%
+636.03K
+24.70%
Jun 09, 2025
State Street Global Advisors (US)
2.71M
4.37%
-624.44K
-18.75%
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
2.45M
3.95%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.42M
2.3%
+46.50K
+3.38%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.27M
2.06%
-71.66K
-5.33%
Mar 31, 2025
查看更多
持股ETF
更新时间: 20 小时前
更新时间: 20 小时前
机构名称
占比
Invesco Biotechnology & Genome ETF
3.93%
Invesco Dorsey Wright Healthcare Momentum ETF
3.07%
ALPS Medical Breakthroughs ETF
2.64%
Invesco S&P SmallCap Health Care ETF
2.02%
Invesco S&P SmallCap 600 Pure Growth ETF
1.86%
ETC 6 Meridian Small Cap Equity ETF
1.43%
Virtus LifeSci Biotech Clinical Trials ETF
1.35%
Inspire Fidelis Multi Factor ETF
0.94%
Invesco S&P SmallCap Quality ETF
0.91%
Cambria Value and Momentum ETF
0.84%
查看更多
Invesco Biotechnology & Genome ETF
占比3.93%
Invesco Dorsey Wright Healthcare Momentum ETF
占比3.07%
ALPS Medical Breakthroughs ETF
占比2.64%
Invesco S&P SmallCap Health Care ETF
占比2.02%
Invesco S&P SmallCap 600 Pure Growth ETF
占比1.86%
ETC 6 Meridian Small Cap Equity ETF
占比1.43%
Virtus LifeSci Biotech Clinical Trials ETF
占比1.35%
Inspire Fidelis Multi Factor ETF
占比0.94%
Invesco S&P SmallCap Quality ETF
占比0.91%
Cambria Value and Momentum ETF
占比0.84%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
